Skip to news
Today’s briefing
JQJO
Latest

Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42% | JQJO

Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%

Tap title to read story

0:00 / 0:41

A late‑stage trial of Moderna and Merck’s melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda, reduced the relative risk of disease recurrence or death by 42% compared with Keytruda alone after a median follow‑up of 24.6 months. The result, disclosed ahead of the European Society for Medical Oncology meeting, met the study’s primary endpoint and was described by analysts as a landmark moment. Shares of both companies fell immediately, with Moderna’s stock dropping nearly 25% and Merck’s falling about 1%. Analysts noted a “sell‑the‑news” reaction to the announcement. The 42% reduction is slightly below the 44% observed in a smaller Phase 2 trial, but still represents a significant clinical benefit.

Published · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Timeline

  1. 2026-08 — Moderna and Merck announce melanoma vaccine trial results
  2. On October 22 2026 Data leak triggers immediate share decline.
  3. On October 22 2026 Merck shares fall by one percent.
  4. On October 22 2026 Moderna shares tumble by twenty‑five percent.

Why it matters

Immediate US impact: Investors react with sharp sell‑off Possible long-term US impact: Potential for future revenue growth Most affected groups: Pharmaceutical investors and oncology patients Reader priority: Understand vaccine efficacy and market response

Coverage notes

Center: Coverage from Reuters, Ars Technica, Scientific American frames this as a developing news story: Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%. Reporting emphasizes verified facts, named sources, and near-term impact for readers. Left: Left-leaning desks covering the same development typically emphasize public impact, institutional accountability, and who is most affected. Right: Right-leaning desks covering the same development typically emphasize practical outcomes, market or security stakes, and institutional response.

Primary report

BioPharma Dive — Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%

Sources

JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.

Editorial policy and corrections · Our team

YouTube Moves Subscriptions Tab

Tap title to read story

0:00 / 0:33

Texas QB Arch Manning Described as Edgy

Tap title to read story

0:00 / 0:26

No Widespread Damage Reported from Newly Publicized PHP Vulnerabilities

Tap title to read story

0:00 / 0:45

Forest Hills Stadium Caps Concerts

Tap title to read story

0:00 / 0:15

Canva Launches First Image‑Generation Model, Canva Craft

Tap title to read story

0:00 / 0:56

Arman Tsarukyan Confirms Upcoming Title Fight

Tap title to read story

0:00 / 0:23

iOS 27 Adds Call Context Feature

Tap title to read story

0:00 / 0:20

Sony Discontinues Last 4K UHD Player

Tap title to read story

0:00 / 0:30

Entrepreneurship linked to longer life

Tap title to read story

0:00 / 0:34

JQJO

Find your next story

Search JQJO’s current coverage.